301033 Medprin Regenerative Medical Technologies
- 40.89
- -0.62-1.49%
Medprin Regenerative Medical Technologies News
The general manager of Maipu Medical (301033.SZ) completed an increase of 7,600 shares
Maipu Medical (301033.SZ) issued an announcement. As of the disclosure date of this announcement, Wang Jianhua, the company's director and general manager, has...
Maipu Medical (301033.SZ) was granted a cumulative increase of 5,200 shares by Director and General Manager Wang Jianhua
Zhitong Finance App News, Maipu Medical (301033.SZ) announced that Wang Jianhua, the company's director and general manager, has already passed halfway through the plan to increase his holdings. Wang Jianhua has increased his holdings by 5,200 shares, accounting for 0.0079% of the company's total share capital. The increase amount is 152,800 yuan (not including transaction fees).
Maipu Medical (301033.SZ) announced first-quarter results, net profit of 149.44,800 yuan, an increase of 91.19% year-on-year
Maipu Medical (301033.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved an operating income of 5...
Maipu Medical (301033.SZ): Achieving revenue of 231 million yuan in 2023, plans to distribute 10 to 4 yuan
Gelonghui, April 18 | Maipu Medical (301033.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 231 million yuan, an increase of 18.24%; net profit attributable to shareholders of listed companies was 408.774 million yuan, up 13.89% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 37.233 million yuan, an increase of 55.54% year on year; basic earnings per share of 0.62 yuan; it plans to distribute a cash dividend of 4.00 yuan (tax included) to all shareholders for every 10 shares.
Medprin Regenerative Medical Technologies Co., Ltd. (SZSE:301033) CEO Yuyu Yuan, the Company's Largest Shareholder Sees 18% Reduction in Holdings Value
Key Insights Medprin Regenerative Medical Technologies' significant insider ownership suggests inherent interests in company's expansion 54% of the business is held by the top 6 shareholders 14%
Maipu Medicine (301033.SZ): Focus on the field of neurosurgery
Gelonghui, March 21丨Maipu Medical (301033.SZ) said on the investor interactive platform that currently the company is focusing on the field of neurosurgery. The main products are implanted medical device products such as artificial hard brain (spine) membrane patches, craniomaxillofacial repair and fixation systems, absorbable regenerated cellulose, and dural medical gel.
Maipu Medical (301033.SZ): Initial repurchase of 581,000 shares involving 1,837,600 yuan
Gelonghui, March 5, 丨 Maipu Medical (301033.SZ) announced that on March 5, 2024, for the first time, the company repurchased 581,000 shares of the company through a special stock repurchase securities account. The number of shares repurchased accounted for 0.0879% of the company's total share capital. The highest transaction price was 32.68 yuan/share, the minimum transaction price was 31.39 yuan/share, and the total repurchase amount was 1,837,600 yuan (not including transaction fees).
Yuan Yuyu, the actual controller of Maipu Medical (301033.SZ), completed a cumulative increase of 65,300 shares
Maipu Medical (301033.SZ) announced that Yuan Yuyu, the actual controller, controlling shareholder, chairman and general manager of the company...
Maipu Medical (301033.SZ): Implementation of the plan for shareholders and directors holding 5% or more of the shares to increase the company's shares completed
Gelonghui, Feb. 26 | Maipu Medical (301033.SZ) announced that as of the disclosure date of this announcement, the shareholder and director of the company, Mr. Yuan Meifu, has been implemented. He has accumulated 38,800 shares of the company's shares through centralized bidding through the Shenzhen Stock Exchange trading system, accounting for 0.06% of the company's total share capital. The increase in holdings was 1,108,501.00 yuan. The increase amount has exceeded the upper limit of the corresponding plan increase amount.
Maipu Medical (301033.SZ): Plans to spend 10 million yuan to 20 million yuan to buy back shares
On February 23, Gelonghui | Maipu Medical (301033.SZ) announced that the company plans to repurchase the issued RMB common stock (A share) shares for employee stock ownership plans or equity incentives. The total capital for the repurchase of shares shall not be less than RMB 10 million and not more than RMB 20 million (all including principal amount). According to the maximum repurchase price of RMB 49 per share and the minimum repurchase amount of RMB 10 million, the estimated number of shares to be repurchased is 204,082 shares, accounting for 0.31% of the company's current total share capital; according to the maximum repurchase price of RMB 49 per share, the repurchase amount
Two directors of Maipu Medical (301033.SZ) completed a total increase of 46,800 shares
Maipu Medical (301033.SZ) announced that Ms. Luo Yahong, the company's director, deputy general manager and financial director, and directors...
Maipu Medical (301033.SZ): Director Yuan Meifu plans to increase the company's shares by 1 million yuan to 2 million yuan
On February 8, Ge Longhui | Maipu Medical (301033.SZ) announced that Mr. Yuan Meifu, the shareholder and director of the company, increased his holdings by 300 shares through the Shenzhen Stock Exchange system through centralized bidding on February 8, 2024, accounting for 0.0005% of the company's total share capital. The increase amount was 8,019 yuan. Within 6 months from February 8, 2024, the initial increase in holdings, Mr. Yuan Meifu plans to continue to increase his holdings by no less than RMB 1 million and no more than RMB 2 million (all including the principal amount, including the initial increase in shares of RMB 8,019).
Maipu Medical (301033.SZ): The actual controller, controlling shareholders, and some directors and executives plan to increase their total holdings of the company by 1.85 million yuan to 3.7 million yuan
Gelonghui, Feb. 7 | Maipu Medical (301033.SZ) announced that the actual controller, controlling shareholders, and some directors and senior management of the company intend to increase their holdings by means of centralized bidding through the Shenzhen Stock Exchange trading system within 6 months (that is, February 7, 2024 to August 6, 2024, except when laws, regulations and related regulations are prohibited). The total proposed increase in holdings is RMB 1.85 million to RMB 3.7 million.
Medprin Regenerative Medical Technologies Co., Ltd. (SZSE:301033) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Medprin Regenerative Medical Technologies (SZSE:301033) has had a rough month with its share price down 15%. However, stock prices are usually driven by a company's financials over the long term, wh
Maipu Medicine (301033.SZ): Products under development, oral absorbable repair film and absorbable multilayer filament regenerated cellulose are all in clinical trials
Gelonghui, December 27丨Maipu Medical (301033.SZ) stated in the investor relations activity record sheet that the company is currently developing products such as oral absorbable repair film and absorbable multi-layer fibrous regenerated cellulose are all in clinical trials. Among them, the clinical trial of absorbable multilayer filament regenerated cellulose oxide successfully completed the enrollment process.
The actual controller of Maipu Medical (301033. SZ) pledged 3.71 million shares
Maipu Medical (301033.SZ) announced that the company recently received a letter from Yuan Yuyu, the actual controller and controlling shareholder of the company...
Insiders Were the Biggest Winners as Medprin Regenerative Medical Technologies Co., Ltd.'s (SZSE:301033) Market Cap Grew by CN¥434m Last Week
Key Insights Insiders appear to have a vested interest in Medprin Regenerative Medical Technologies' growth, as seen by their sizeable ownership 54% of the business is held by the top 6 shareholders
Maipu Medical (301033.SZ) released the first three quarter results, net profit of 25.424,800 yuan, a decrease of 15.35%
Maipu Medical (301033.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 1...
Shenzhen Kaiying, the main shareholder of Maipu Medicine (301033.SZ), terminated the holdings reduction plan ahead of schedule without reducing holdings
Maipu Medical (301033.SZ) announced that the shareholder of the company holds more than 5% of the shares, Shenzhen Kaiying Technology Co., Ltd. (“...
Interpretation of Maipu Medical's 2023 Interim Report: Net revenue and profit both declined, and net cash flow increased sharply
According to Maipu Medical's 2023 interim report, the company's revenue was 85,715,500.25 yuan, down 9.80% from 95,024,904.82 yuan in the same period last year. This indicates that the scale of the company's business activity has shrunk during the reporting period. Meanwhile, net profit attributable to shareholders of listed companies was 11,891,627.77 yuan, down 43.98% from 21,225,821.94 yuan in the same period last year. This could mean that the company's profitability declined during the reporting period. However, net profit attributable to shareholders of a listed company after deducting non-recurring profit and loss is 9
Analysis
Price Target
No Data
